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Pertussis causes a large number of cases and hospitalizations in Catalonia and Navarra.
We made a study of household cases of pertussis during 2012 and 2013 in order to identify
risk factors for hospitalization in pertussis cases. Each primary case reported triggered the
study of their contacts. Close contacts at home and people who were in contact for >2 hours
during the transmission period of cases were included. The adjusted OR and 95% confidence
intervals (CI) was calculated using logistic regression. A total of 1124 pertussis cases were
detected, of which 14.9%were hospitalized. Inspiratory whoop (aOR: 1.64; CI: 1.02–2.65),
apnoea (aOR: 2.47; CI: 1.51–4.03) and cyanosis (aOR: 15.51; CI: 1.87–128.09) were more
common in hospitalized than in outpatient cases. Hospitalization occurred in 8.7% of cor-
rectly-vaccinated cases, 41.1% of non-vaccinated cases and 9.4% of partially-vaccinated
cases. In conclusion, inspiratory whoop, apnoea and cyanosis were associated factors to
hospitalization while vaccination reduced hospitalizations due to pertussis.
Introduction
Pertussis disease causes a high number of cases and hospitalizations even though it is a prevent-
able disease with high vaccination coverages [1–3]. The vaccination schedule of pertussis in
Spain includes the first series of vaccine at 2, 4, and 6 months and two booster doses at 18
months and 4–6 years [4,5]. Vaccination coverages in Spain were> 95% for the first series of
vaccination, up to 90% for the first booster dose, and around 80% for the second booster dose
in 2011 [6, 7]. In Spain, notification of pertussis disease is mandatory and must be reported by
physicians to the Health Department. In recent years, the incidence of pertussis has increased
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in Catalonia and Navarra, in other regions in Spain, and worldwide [8], and an increase in hos-
pitalizations has been observed. Reported reasons for the increasing incidence include
improvements in diagnostic methods [9–10], the decrease in the protection provided by per-
tussis vaccination over time, and the fact that vaccination, or having the disease, does not pro-
vide life-long protection against new infection. Additional suggested reasons include waning
immunity [11], the change from the whole cell to the acellular vaccine, vaccine failure, and
changes in B. pertussis strains [12–14].
However, some reports suggest that vaccination with at least one dose reduces the risk of
hospitalization [15–16]. Determination of risk factors for hospitalization could aid vaccination
and decrease hospitalization due to pertussis and therefore reduce the disease burden for the
public health system.
The aim of this study was to determine risk factors for hospitalization in cases of pertussis
in two Spanish regions (Catalonia and Navarra).
Methods
Between January 2012 and December 2013, all confirmed pertussis cases and their contacts
were reported to the surveillance system in Catalonia and Navarra, which have a population of
8,200,000 (17.4% of the Spanish population). Pertussis cases were defined as patients with 2
weeks of cough with other symptom such as paroxysms, inspiratory whoop, posttussive vomit-
ing or apnoea, accompanied by one of the following: laboratory confirmation by real-time
polymerase chain reaction (PCR) or culture or epidemiologic link with a laboratory-confirmed
case. Bacterial culture were prepared with selective charcoal agar (5%) plates (Oxoid, Basing-
stoke, UK), defibrinated human blood (10%) and cephalexin (40mg/l) (Selective supplement
Bordetella, Oxoid, Basingstoke, UK). The plates were incubated in a humid atmosphere at 37°C
(±2°C) and were examined daily for 5 days. The real-time PCR target used in the study was
insertion sequence IS481 of B. pertussis. This sequence presents a high copy number in B. per-
tussis (about 200 copies) and a low copy number in other Bordetella species as B. holmesii or B.
bronchiseptica. A second real-time PCR was performed in samples with Ct values above 35,
and these samples were also concentrated (x4) by easyMAG (BioMerieux Laboratories, Marcy
l’Etoile, France). The target insertion sequence was IS1002, which allow discrimination
between other Bordetella spp and B. pertussis, as low copy numbers are found in B. pertussis.
A modified definition was used for patients aged< 1 year, in whom coughing could last< 2
weeks, but had to be accompanied by paroxysm and another symptom. Household contacts
were defined as usual residents of the house of the index case; other contacts were defined as
people who spent> 2 hours in the house of the index case during the transmission period of
the disease.
Each contact was surveyed about exposure to the case, respiratory symptoms, doses of vac-
cine received and chemoprophylaxis. Once the index case was detected, we identified all house-
hold and other contacts, who were surveyed immediately after identification. In addition, both
cases and contacts were followed for 28 days after the date of report in order to determine com-
plications and the appearance of secondary cases.
Contacts with cough or other symptom related to pertussis were laboratory tested to con-
firm or rule out the disease. Some contacts became cases after laboratory testing and were
included as cases, not as contacts. Pertussis index cases were defined as the first case reported
and diagnosed that generated the household study. After the household study, index cases were
classified as primary case, co-primary case or secondary case. Primary cases were cases without
an epidemiological link to a pertussis case previously detected in the house. Co-primary cases
were cases epidemiologically linked to a pertussis case diagnosed in the household with onset
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of symptoms between 0 and 6 days after the other pertussis case. Secondary cases were cases
with an epidemiological link with a pertussis case previously detected in the household with
onset of symptoms between 7 and 28 days after the other pertussis case. Symptoms from cases
were obtained from clinical reports, from the attending physicians and by interview with cases
or their parents or tutors. The following variables were collected in pertussis cases: clinical fea-
tures, age, length of hospitalization, laboratory test used, vaccination status, date of onset of
symptoms, date of diagnosis, vaccination status and type of case (primary or secondary). The
following variables were collected in contacts: exposure to the case, respiratory symptoms,
doses of vaccine received and chemoprophylaxis.
Diagnostic delay was calculated as the days between the onset of symptoms and the day of
diagnosis. Cases were classified according to the vaccination status as follows: Correctly-vacci-
nated cases were cases that had received the number of doses corresponding to their age (and
had received at least one dose). Non-vaccinated cases were cases which had not received any
dose of vaccine. Partially-vaccinated cases were cases which had received some but not all vac-
cinations corresponding to their age. The Chi square test was used to compare the vaccination
status.
The odds ratio (OR) and 95% confidence intervals (CI) between hospitalized and outpatient
cases were calculated to determine the variables influencing the risk of hospitalization. To con-
trol for possible confounding variables, the adjusted OR was calculated using logistic regres-
sion, including other variables, such as symptoms and vaccination status, in the model. We
also stratified the OR by age.
Population figures were taken from the National Institute of Statistics (INE) [17]. The statis-
tical analysis was performed using the SPSS v.18 package. Statistical significance was estab-
lished as α = 0.05.
The study was conducted according to the principles expressed in the Declaration of Hel-
sinki. All cases included in the study received detailed information about the aims of the study.
We first obtained verbal consent to participate and then written consent from all cases. When
cases were minors, consent was obtained from relatives, carers or guardian. The study was
approved by the Ethics Committee of Hospital Sant Joan de Deu in Barcelona, Spain.
Results
In the study period, 668 pertussis cases were reported to surveillance units and included in the
study. These generated 2793 household contacts, 456 of whom became pertussis cases and gen-
erated 59 new household contacts. Therefore, 1124 pertussis cases occurred during the study,
of which 536 (47.7%) were male and 588 (52.3%) female.
Seven hundred and thirty-two cases were determined by PCR, 5 by culture, 32 by both PCR
and culture, and 355 by epidemiological link. Seven hundred and thirty eight (65.7%) cases
were classified as primary or co-primary and 386 (34.3%) as secondary.
Table 1 shows the median age, duration of cough and diagnostic delay in hospitalized and
outpatient cases.
One hundred and sixty-seven (14.9%) cases were hospitalized, 936 (83.3%) were outpatient
cases and no information was available in 21 cases. The hospitalization rate was 1.01 per
100,000 inhabitants. Eighty-four hospitalized cases (50.3%) were male and 83 (49.7%) female
(p = 0.511). Eighty-two (49.1%) cases were hospitalized in 2012 and 85 (50.9%) in 2013
(p = 0.221).
Of the 167 hospitalized cases, 163 (97.6%) were index cases, of which 100 (61.3%) were pri-
mary or co-primary cases and 63 secondary cases. Of the 4 cases that were not index cases, 3
(75.0%) were primary cases and 1 was a secondary case. Secondary hospitalized cases acquired
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the infection most frequently from the mother (26.5%), siblings (23.4%), the father (20.3%),
other relatives (20.3%) and grandparents (9.5%).
One hundred and fifty four hospitalized cases (92.2%) were confirmed by PCR, 8 (4.8%) by
both PCR and a positive culture test, 1 (0.6%) by a positive culture and 4 cases (2.4%) were epi-
demiologically-linked to a previous laboratory-confirmed case.
Differences in age group between outpatient and hospitalized cases are shown in Fig 1. Of
hospitalized cases, 91% were aged< 6 months, while 34% of outpatient cases were aged> 15
years.
Table 2 shows the symptoms in hospitalized and outpatient cases. Cough 2 weeks was
excluded from the table, as it was mandatory in reporting a case. The adjusted OR for symp-
toms shows that inspiratory whoop, apnoea and cyanosis were associated with hospitalization.
In pertussis cases aged 0 to 6 months, apnoea was associated with hospitalization (S1 Table).
The vaccination status was known in 905 (81.5%) cases. Table 3 shows the vaccination sta-
tus in hospitalized and outpatient cases.
There were fewer hospitalizations in correctly-vaccinated cases than in non-vaccinated
cases (p<0.001), and fewer hospitalizations in partially-vaccinated cases than in non-vacci-
nated cases (p<0.001). Of hospitalized cases, 56 had received some dose of vaccine: 41 had
received 1 dose (73.2%), 7 cases 2 doses (12.5%), 3 cases 3 doses (5.3%), 3 cases 4 doses (5.3%)
and 2 cases had received 5 doses (3.7%).
Discussion
A large number of pertussis cases were detected in 2012 and 2013 in Catalonia and Navarra, of
which approximately 15% were hospitalized (> 90% were aged<1 year). More than half the
Table 1. Age, duration of cough and diagnostic delay in pertussis cases.
Cases Hospitalized (n = 167)median (range) Outpatient (n = 936)median (range) p value
Age (years) 0 (0–50) 10 (0–87) <0.001
Duration of cough (days) 30 (4–98) 30 (3–112) 0.326
Diagnostic delay (days) 10 (1–67) 18 (0–136) <0.001
doi:10.1371/journal.pone.0139993.t001
Fig 1. Number of hospitalized and outpatient pertussis cases according to age group.mo. months; y. years.
doi:10.1371/journal.pone.0139993.g001
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cases detected were primary or co-primary cases, an important factor for both early treatment
and breaking the transmission of the disease.
Our results show that some symptoms were more frequent in hospitalized than in outpa-
tient cases, including inspiratory whoop, apnoea and cyanosis (which is not a symptom but a
complication of the disease). A New Zealand study found that paroxysmal cough and cyanosis
were predictive factors for not discharging a case from hospital, in order to avoid readmission
[18]. A Swiss study found that hospitalized cases more frequently had cyanosis [19].
We found a reduction in hospitalizations when patients were correctly vaccinated or par-
tially vaccinated. This reinforces the importance of vaccination and suggests that vaccination
reduces disease severity and protects against hospitalization. Similar conclusions have been
reported by other authors, and in some studies one dose of vaccine was sufficient to produce
this reduction [15–16, 19–21].
Some studies have reported that whole cell pertussis vaccine offers greater protection than the
acellular vaccine. We could not analyse this factor, as all hospitalized cases in our study were
aged<10 years (except 1 case aged<45 years with unknown vaccination status) and all were
vaccinated with the acellular vaccine, which has been available in Catalonia since 2002 [22].
Previous studies in Catalonia found a large percentage of pertussis cases in infants [23–25].
In our study, which included active surveillance, a large number of cases in patients aged 15–44
years were detected. Normally a diagnosis of pertussis is not made in this age group as they
have less-severe disease than infants [26–27]. However, several studies in different countries
have found that the age pattern of pertussis has changed and the incidence of cases in adoles-
cents and adults has increased [28–33]. This may be because the vaccination coverage in older
people is lower than in infants and also because of a loss of immunity [34].
Several studies have found that unreported and misdiagnosed cases are a public health problem
[35–36]. Our study avoided this problem because we made active surveillance. For this reason, we
found a higher incidence in adults in Catalonia and Navarra than previously described [6, 8].
A limitation of the study is the large number of epidemiologists involved. Although all epi-
demiologists applied the same protocol, we cannot rule out differences in the interpretation of
Table 2. Predictive symptoms in hospitalized and outpatient pertussis cases.
Hospitalized n = 167 Outpatient n = 936 raw OR (95%CI) p value adjusted ORa (95%CI) p value
Paroxysmal cough 153 771 2.66 (1.44–4.91) 0.002 2.21 (0.91–5.37) 0.081
Inspiratory whoop 94 303 2.82 (2.01–3.97) <0.001 1.64 (1.02–2.65) 0.040
Posttussive vomiting 93 332 2.40 (1.71–3.37) <0.001 1.04 (0.64–1.67) 0.869
Apnoea 89 160 5.66 (3.98–8.05) <0.001 2.47 (1.51–4.03) <0.001
Fever 25 77 1.96 (1.20–3.18) 0.007 1.26 (0.63–2.52) 0.514
Cyanosis 12 1 74.46 (9.61–576.98) <0.001 15.51 (1.87–128.09) 0.011
Pneumonia 5 6 4.81 (1.45–15.95) 0.010 33.58 (0.17–6395.84) 0.189
a. Adjusted for the following variables: Symptoms, Age and Vaccination status.
doi:10.1371/journal.pone.0139993.t002
Table 3. Vaccination status in hospitalized and outpatient cases.
Cases Hospitalized (n = 167) n (%) Outpatient (n = 738) n (%)
Correctly vaccinated (n = 539) 47 (8.7) 492 (91.3)
Partially vaccinated (n = 96) 9 (9.4) 87 (90.6)
Non-vaccinated (n = 270) 111 (41.1) 159 (58.9)
doi:10.1371/journal.pone.0139993.t003
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some variables. However, we believe this did not affect the results, as the Working Group made
a considerable effort to correct possible differences in data interpretation.
Regarding PCR diagnosis, B. bronchiseptica strains that contain a copy of IS481 (it is esti-
mated that IS481 is present in only 1% of B. bronchiseptica) could by erroneously identified as
B. pertussis [37].
In conclusion, we found that inspiratory whoop, apnoea and cyanosis were good predictors
of hospitalization in pertussis cases. Vaccination reduces the disease severity and
hospitalizations.
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